Par Pharmaceutical Inc, one of the operating companies of Endo International plc (OTC: ENDPQ), announced on Friday that it has started shipping the first generic version of Allergan's Pylera(R) (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 140 mg, 125 mg and 125 mg capsules in the US.

The company has taken this step subsequent to US Food and Drug Administration approval of its Abbreviated New Drug Application.

Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, along with omeprazole, are aimed at treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.